Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study

Journal of Affective Disorders

Volumn 207, Issue , 2017, Pages 114-120

  Mansur, Rodrigo B ^a,b   Ahmed, Juhie ^a   Cha, Danielle S ^a   Woldeyohannes, Hanna O ^a   Subramaniapillai, Mehala ^a   Lovshin, Julie ^c   Lee, Jung G ^a,d   Lee, Jae Hon ^a,e   Brietzke, Elisa ^b   Reininghaus, Eva Z ^f   Sim, Kang ^g   Vinberg, Maj ^h   Rasgon, Natalie ⁱ   Hajek, Tomas ^j   McIntyre, Roger S ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF TORONTO   (Canada)

^d Inje University   (South Korea)

^e Samsung Medical Center   (South Korea)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g INSTITUTE OF MENTAL HEALTH   (Singapore)

^h UNIVERSITY OF COPENHAGEN   (Denmark)

ⁱ STANFORD UNIVERSITY   (United States)

^j DALHOUSIE UNIVERSITY   (Canada)

more..

Author keywords

Bipolar disorder; Cognition; Glucagon like peptide 1; Insulin resistance; Liraglutide; Major depressive disorder

Indexed keywords

AMYLASE; ANTIDEPRESSANT AGENT; INSULIN; LIRAGLUTIDE; MOOD STABILIZER; NEUROLEPTIC AGENT; TRIACYLGLYCEROL LIPASE; INCRETIN;

ADULT; AMYLASE BLOOD LEVEL; ARTICLE; BIPOLAR DISORDER; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; DIGIT SYMBOL SUBSTITUTION TEST; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; EPIGASTRIC FULLNESS; EXECUTIVE FUNCTION; FEMALE; HUMAN; INDIGESTION; INSULIN RESISTANCE; MAJOR DEPRESSION; MALE; METABOLIC PARAMETERS; MOOD DISORDER; NAUSEA; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; RATING SCALE; REY AUDITORY VERBAL LEARNING TEST; STROOP TEST; TRAIL MAKING TEST; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; AFFECT; CHEMICALLY INDUCED; COGNITION; LEARNING; MIDDLE AGED; PSYCHOLOGY; TREATMENT OUTCOME;

ADULT; AFFECT; BIPOLAR DISORDER; COGNITION; COGNITIVE DYSFUNCTION; DEPRESSIVE DISORDER, MAJOR; EXECUTIVE FUNCTION; FEMALE; HUMANS; INCRETINS; LIRAGLUTIDE; MALE; MIDDLE AGED; MOOD DISORDERS; NAUSEA; PILOT PROJECTS; STROOP TEST; TREATMENT OUTCOME; VERBAL LEARNING;

EID: 85007593139     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2016.09.056     Document Type: Article

References (88)

1. ICH Harmonised Tripartite Guideline E6: Guideline for Good Clinical Practice, 1996. p. 〈http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073122.pdf〉.
2. (WMA), W.M.A., 2008 (WMA), W.M.A, 2008. Declaration of Helsinki: ethical principles for medical research involving human subjects., p. 〈http://www.wma.net/en/30publications/10policies/b33/〉.
3. Alvarez, E., Martinez, M.D., Roncero, I., Chowen, J.A., Garcia-Cuartero, B., Gispert, J.D., Sanz, C., Vazquez, P., Maldonado, A., de Caceres, J., Desco, M., Pozo, M.A., Blazquez, E., The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J. Neurochem. 92 (2005), 798–806.
4. Bomfim, T.R., Forny-Germano, L., Sathler, L.B., Brito-Moreira, J., Houzel, J.C., Decker, H., Silverman, M.A., Kazi, H., Melo, H.M., McClean, P.L., Holscher, C., Arnold, S.E., Talbot, K., Klein, W.L., Munoz, D.P., Ferreira, S.T., De Felice, F.G., An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Abeta oligomers. J. Clin. Investig. 122 (2012), 1339–1353.
5. Bourne, C., Aydemir, O., Balanza-Martinez, V., Bora, E., Brissos, S., Cavanagh, J.T., Clark, L., Cubukcuoglu, Z., Dias, V.V., Dittmann, S., Ferrier, I.N., Fleck, D.E., Frangou, S., Gallagher, P., Jones, L., Kieseppa, T., Martinez-Aran, A., Melle, I., Moore, P.B., Mur, M., Pfennig, A., Raust, A., Senturk, V., Simonsen, C., Smith, D.J., Bio, D.S., Soeiro-de-Souza, M.G., Stoddart, S.D., Sundet, K., Szoke, A., Thompson, J.M., Torrent, C., Zalla, T., Craddock, N., Andreassen, O.A., Leboyer, M., Vieta, E., Bauer, M., Worhunsky, P.D., Tzagarakis, C., Rogers, R.D., Geddes, J.R., Goodwin, G.M., Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr. Scand. 128 (2013), 149–162.
6. Bove, R.M., Brick, D.J., Healy, B.C., Mancuso, S.M., Gerweck, A.V., Bredella, M.A., Sherman, J.C., Miller, K.K., Metabolic and endocrine correlates of cognitive function in healthy young women. Obesity 21 (2013), 1343–1349.
7. Bredemeier, K., Miller, I.W., Executive function and suicidality: a systematic qualitative review. Clin. Psychol. Rev. 40 (2015), 170–183.
8. Cabou, C., Campistron, G., Marsollier, N., Leloup, C., Cruciani-Guglielmacci, C., Penicaud, L., Drucker, D.J., Magnan, C., Burcelin, R., Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes 57 (2008), 2577–2587.
9. Calkin, C.V., Ruzickova, M., Uher, R., Hajek, T., Slaney, C.M., Garnham, J.S., O'Donovan, M.C., Alda, M., Insulin resistance and outcome in bipolar disorder. Br. J. Psychiatry 206 (2015), 52–57.
10. CohenJ., 1988. Statistical power analysis for the behavioral sciences, 2nd ed. L. Erlbaum Associates, Hillsdale, N.J.
11. Crump, C., Sundquist, K., Winkleby, M.A., Sundquist, J., Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry 70 (2013), 931–939.
12. Daniele G., Iozzo P., Molina-Carrion M., Lancaster J., Ciociaro D., Cersosimo E., Tripathy D., Triplitt C., Fox P., Musi N., De Fronzo R., Gastaldelli A., 2015 Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated with Glucose Homeostasis and Reward System. Diabetes.
13. Darsalia, V., Mansouri, S., Ortsater, H., Olverling, A., Nozadze, N., Kappe, C., Iverfeldt, K., Tracy, L.M., Grankvist, N., Sjoholm, A., Patrone, C., Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats. Clin. Sci. (Lond.) 122 (2012), 473–483.
14. Depp, C.A., Mausbach, B.T., Harmell, A.L., Savla, G.N., Bowie, C.R., Harvey, P.D., Patterson, T.L., Meta-analysis of the association between cognitive abilities and everyday functioning in bipolar disorder. Bipolar Disord. 14 (2012), 217–226.
15. Dias, V.V., Balanza-Martinez, V., Soeiro-de-Souza, M.G., Moreno, R.A., Figueira, M.L., Machado-Vieira, R., Vieta, E., Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. Acta Psychiatr. Scand. 126 (2012), 315–331.
16. Drucker, D.J., Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26 (2003), 2929–2940.
17. During, M.J., Cao, L., Zuzga, D.S., Francis, J.S., Fitzsimons, H.L., Jiao, X., Bland, R.J., Klugmann, M., Banks, W.A., Drucker, D.J., Haile, C.N., 2003. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 9, 1173–1179.
18. Engler, H., Forsberg, A., Almkvist, O., Blomquist, G., Larsson, E., Savitcheva, I., Wall, A., Ringheim, A., Langstrom, B., Nordberg, A., Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129 (2006), 2856–2866.
19. Farr, O.M., Sofopoulos, M., Tsoukas, M.A., Dincer, F., Thakkar, B., Sahin-Efe, A., Filippaios, A., Bowers, J., Srnka, A., Gavrieli, A., Ko, B.J., Liakou, C., Kanyuch, N., Tseleni-Balafouta, S., Mantzoros, C.S., GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Diabetologia 59 (2016), 954–965.
20. Gault, V.A., Holscher, C., GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur. J. Pharm. 587 (2008), 112–117.
21. Geijselaers, S.L., Sep, S.J., Stehouwer, C.D., Biessels, G.J., 2014. Glucose regulation, cognition, and brain MRI in type 2 diabetes: a systematic review. Lancet Diabetes Endocrinol.
22. Gejl, M., Egefjord, L., Lerche, S., Vang, K., Bibby, B.M., Holst, J.J., Mengel, A., Moller, N., Rungby, J., Brock, B., Gjedde, A., Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia. J. Cereb. Blood Flow. Metab. 32 (2012), 2146–2152.
23. Gejl, M., Gjedde, A., Egefjord, L., Moller, A., Hansen, S.B., Vang, K., Rodell, A., Braendgaard, H., Gottrup, H., Schacht, A., Moller, N., Brock, B., Rungby, J., In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: randomized, Placebo-Controlled, Double-Blind Clinical Trial. Front Aging Neurosci., 8, 2016, 108.
24. Gengler, S., McClean, P.L., McCurtin, R., Gault, V.A., Holscher, C., Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol. Aging 33 (2012), 265–276.
25. Goldstein, B.I., Liu, S.M., Schaffer, A., Sala, R., Blanco, C., Obesity and the three-year longitudinal course of bipolar disorder. Bipolar Disord. 15 (2013), 284–293.
26. Gomes, F.A., Almeida, K.M., Magalhaes, P.V., Caetano, S.C., Kauer-Sant'Anna, M., Lafer, B., Kapczinski, F., Cardiovascular risk factors in outpatients with bipolar disorder: a report from the Brazilian Research Network in Bipolar Disorder. Rev. Bras. Psiquiatr 35 (2013), 126–130.
27. Gualtieri, C.T., Morgan, D.W., The frequency of cognitive impairment in patients with anxiety, depression, and bipolar disorder: an unaccounted source of variance in clinical trials. J. Clin. Psychiatry 69 (2008), 1122–1130.
28. Hajek, T., Calkin, C., Blagdon, R., Slaney, C., Alda, M., Type 2 diabetes mellitus: a potentially modifiable risk factor for neurochemical brain changes in bipolar disorders. Biol. Psychiatry 77 (2015), 295–303.
29. Hajek, T., Calkin, C., Blagdon, R., Slaney, C., Uher, R., Alda, M., Insulin resistance, diabetes mellitus, and brain structure in bipolar disorders. Neuropsychopharmacology 39 (2014), 2910–2918.
30. Handley, T.E., Ventura, A.D., Browne, J.L., Rich, J., Attia, J.R., Reddy, P., Pouwer, F., Speight, J., 2015. Suicidal ideation reported by adults with Type 1 or Type 2 diabetes: results from Diabetes MILES-Australia. Diabet. Med.
31. Heni, M., Kullmann, S., Ketterer, C., Guthoff, M., Linder, K., Wagner, R., Stingl, K.T., Veit, R., Staiger, H., Haring, H.U., Preissl, H., Fritsche, A., Nasal insulin changes peripheral insulin sensitivity simultaneously with altered activity in homeostatic and reward-related human brain regions. Diabetologia 55 (2012), 1773–1782.
32. Iwai, T., Suzuki, M., Kobayashi, K., Mori, K., Mogi, Y., Oka, J., The influences of juvenile diabetes on memory and hippocampal plasticity in rats: improving effects of glucagon-like peptide-1. Neurosci. Res 64 (2009), 67–74.
33. Karlamangla, A.S., Miller-Martinez, D., Lachman, M.E., Tun, P.A., Koretz, B.K., Seeman, T.E., Biological correlates of adult cognition: midlife in the United States (MIDUS). Neurobiol. Aging 35 (2014), 387–394.
34. Kastin, A.J., Akerstrom, V., Pan, W., Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J. Mol. Neurosci. 18 (2002), 7–14.
35. Katsurada, K., Maejima, Y., Nakata, M., Kodaira, M., Suyama, S., Iwasaki, Y., Kario, K., Yada, T., Endogenous GLP-1 acts on paraventricular nucleus to suppress feeding: projection from nucleus tractus solitarius and activation of corticotropin-releasing hormone, nesfatin-1 and oxytocin neurons. Biochem. Biophys. Res. Commun. 451 (2014), 276–281.
36. Keilp, J.G., Gorlyn, M., Russell, M., Oquendo, M.A., Burke, A.K., Harkavy-Friedman, J., Mann, J.J., Neuropsychological function and suicidal behavior: attention control, memory and executive dysfunction in suicide attempt. Psychol. Med. 43 (2013), 539–551.
37. Kessler, R.C., Berglund, P., Demler, O., Jin, R., Merikangas, K.R., Walters, E.E., Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62 (2005), 593–602.
38. Kessler, R.C., Merikangas, K.R., Wang, P.S., The prevalence and correlates of workplace depression in the national comorbidity survey replication. J. Occup. Environ. Med 50 (2008), 381–390.
39. Kleine-Budde, K., Touil, E., Moock, J., Bramesfeld, A., Kawohl, W., Rossler, W., Cost of illness for bipolar disorder: a systematic review of the economic burden. Bipolar Disord. 16 (2014), 337–353.
40. Kullmann, S., Heni, M., Fritsche, A., Preissl, H., Insulin action in the human brain: evidence from neuroimaging studies. J. Neuroendocr. 27 (2015), 419–423.
41. Kullmann, S., Heni, M., Veit, R., Scheffler, K., Machann, J., Haring, H.U., Fritsche, A., Preissl, H., Selective insulin resistance in homeostatic and cognitive control brain areas in overweight and obese adults. Diabetes Care 38 (2015), 1044–1050.
42. Levy, J.C., Matthews, D.R., Hermans, M.P., Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21 (1998), 2191–2192.
43. Long-Smith, C.M., Manning, S., McClean, P.L., Coakley, M.F., O'Halloran, D.J., Holscher, C., O'Neill, C., The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-beta plaque and glial pathology in a mouse model of Alzheimer's disease. Neuromolecular Med. 15 (2013), 102–114.
44. Mahableshwarkar, A.R., Zajecka, J., Jacobson, W., Chen, Y., Keefe, R.S., A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology 40 (2015), 2025–2037.
45. Malloy-Diniz, L.F., Neves, F.S., Abrantes, S.S., Fuentes, D., Correa, H., Suicide behavior and neuropsychological assessment of type I bipolar patients. J. Affect Disord. 112 (2009), 231–236.
46. Mansur, R.B., Brietzke, E., McIntyre, R.S., Is there a “metabolic-mood syndrome”? A review of the relationship between obesity and mood disorders. Neurosci. Biobehav. Rev. 52 (2015), 89–104.
47. Mansur, R.B., Rizzo, L.B., Santos, C.M., Asevedo, A., Cunha, G.R., Noto, M.N., Pedrini, M., Zeni, M., Cordeiro, C., McIntyre, R.S., Brietzke, E., Adipokines, metabolic dysfunction and illness course in bipolar disorder. J. Psychiatr. Res. 74 (2016), 63–69.
48. Mansur, R.B., Rizzo, L.B., Santos, C.M., Asevedo, E., Cunha, G.R., Noto, M.N., Pedrini, M., Zeni-Graiff, M., Gouvea, E.S., Cordeiro, Q., Reininghaus, E.Z., McIntyre, R.S., Brietzke, E., Bipolar disorder course, impaired glucose metabolism and antioxidant enzymes activities: a preliminary report. J. Psychiatr. Res. 80 (2016), 38–44.
49. Mansur, R.B., Santos, C.M., Rizzo, L.B., Asevedo, E., Cunha, G.R., Noto, M.N., Pedrini, M., Zeni-Graiff, M., Cordeiro, Q., Vinberg, M., Kapczinski, F., McIntyre, R.S., Brietzke, E., Brain-derived neurotrophic factor, impaired glucose metabolism, and bipolar disorder course. Bipolar Disord. 18 (2016), 373–378.
50. Martino, D.J., Strejilevich, S.A., Scapola, M., Igoa, A., Marengo, E., Ais, E.D., Perinot, L., Heterogeneity in cognitive functioning among patients with bipolar disorder. J. Affect Disord. 109 (2008), 149–156.
51. McClean, P.L., Gault, V.A., Harriott, P., Holscher, C., Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. Eur. J. Pharmacol. 630 (2010), 158–162.
52. McClean, P.L., Holscher, C., Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. Neuropharmacology 76 (2014), 57–67.
53. McClean, P.L., Parthsarathy, V., Faivre, E., Holscher, C., The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 31 (2011), 6587–6594.
54. McIntyre, R.S., Cha, D.S., Soczynska, J.K., Woldeyohannes, H.O., Gallaugher, L.A., Kudlow, P., Alsuwaidan, M., Baskaran, A., Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depression Anxiety 30 (2013), 515–527.
55. McIntyre, R.S., Danilewitz, M., Liauw, S.S., Kemp, D.E., Nguyen, H.T., Kahn, L.S., Kucyi, A., Soczynska, J.K., Woldeyohannes, H.O., Lachowski, A., Kim, B., Nathanson, J., Alsuwaidan, M., Taylor, V.H., Bipolar disorder and metabolic syndrome: an international perspective. J. Affect. Disord. 126 (2010), 366–387.
56. McIntyre, R.S., Harrison, J., Loft, H., Jacobson, W., Olsen, C.K., 2016. The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder (MDD): a Meta-Analysis of Three Randomized Controlled Trials. Int. J. Neuropsychopharmacol.
57. McIntyre, R.S., Lophaven, S., Olsen, C.K., A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int. J. Neuropsychopharmacol. 17 (2014), 1557–1567.
58. McIntyre, R.S., Powell, A.M., Kaidanovich-Beilin, O., Soczynska, J.K., Alsuwaidan, M., Woldeyohannes, H.O., Kim, A.S., Gallaugher, L.A., The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders. Behav. Brain Res. 237 (2013), 164–171.
59. McIntyre, R.S., Xiao, H.X., Syeda, K., Vinberg, M., Carvalho, A.F., Mansur, R.B., Maruschak, N., Cha, D.S., The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder. CNS Drugs 29 (2015), 577–589.
60. Mosconi, L., Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging 32 (2005), 486–510.
61. Naiberg, M.R., Newton, D.F., Collins, J.E., Dickstein, D.P., Bowie, C.R., Goldstein, B.I., Elevated triglycerides are associated with decreased executive function among adolescents with bipolar disorder. Acta Psychiatr. Scand. 134 (2016), 241–248.
62. Naismith, S.L., Longley, W.A., Scott, E.M., Hickie, I.B., Disability in major depression related to self-rated and objectively-measured cognitive deficits: a preliminary study. BMC Psychiatry, 7, 2007, 32.
63. Parkinson, J.R., Chaudhri, O.B., Kuo, Y.T., Field, B.C., Herlihy, A.H., Dhillo, W.S., Ghatei, M.A., Bloom, S.R., Bell, J.D., Differential patterns of neuronal activation in the brainstem and hypothalamus following peripheral injection of GLP-1, oxyntomodulin and lithium chloride in mice detected by manganese-enhanced magnetic resonance imaging (MEMRI). Neuroimage 44 (2009), 1022–1031.
64. Perugi, G., Quaranta, G., Belletti, S., Casalini, F., Mosti, N., Toni, C., Dell'Osso, L., General medical conditions in 347 bipolar disorder patients: clinical correlates of metabolic and autoimmune-allergic diseases. J. Affect. Disord. 170 (2015), 95–103.
65. Pipatpiboon, N., Pintana, H., Pratchayasakul, W., Chattipakorn, N., Chattipakorn, S.C., DPP4-inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption. Eur. J. Neurosci. 37 (2013), 839–849.
66. Porter, D.W., Kerr, B.D., Flatt, P.R., Holscher, C., Gault, V.A., Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance. Diabetes Obes. Metab. 12 (2010), 891–899.
67. Raison, C.L., Rutherford, R.E., Woolwine, B.J., Shuo, C., Schettler, P., Drake, D.F., Haroon, E., Miller, A.H., A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA. Psychiatry 70 (2013), 31–41.
68. Ram, J., Snehalatha, C., Nanditha, A., Selvam, S., Shetty, S.A., Godsland, I.F., Johnston, D.G., Ramachandran, A., Hypertriglyceridaemic waist phenotype as a simple predictive marker of incident diabetes in Asian-Indian men with prediabetes. Diabet. Med. 31 (2014), 1542–1549.
69. Richard, J.E., Farkas, I., Anesten, F., Anderberg, R.H., Dickson, S.L., Gribble, F.M., Reimann, F., Jansson, J.O., Liposits, Z., Skibicka, K.P., GLP-1 receptor stimulation of the lateral parabrachial nucleus reduces food intake: neuroanatomical, electrophysiological, and behavioral evidence. Endocrinology 155 (2014), 4356–4367.
70. Rinaman, L., Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus. Am. J. Physiol. 277 (1999), R582–R590.
71. Rosenblat, J.D., Kakar, R., McIntyre, R.S., 2016. The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trials. Int. J. Neuropsychopharmacol. 19.
72. Ruzickova, M., Slaney, C., Garnham, J., Alda, M., Clinical features of bipolar disorder with and without comorbid diabetes mellitus. Can. J. Psychiatry 48 (2003), 458–461.
73. Schlogl, H., Kabisch, S., Horstmann, A., Lohmann, G., Muller, K., Lepsien, J., Busse-Voigt, F., Kratzsch, J., Pleger, B., Villringer, A., Stumvoll, M., Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity. Diabetes Care 36 (2013), 1933–1940.
74. Shapiro, J., Mindra, S., Timmins, V., Swampillai, B., Scavone, A., Collinger, K., Collins, J., Goldstein, B.I., 2016. Controlled study of obesity among adolescents with bipolar disorder. J. Child Adolesc. Psychopharmacol.
75. Shelton, R.C., Pencina, M.J., Barrentine, L.W., Ruiz, J.A., Fava, M., Zajecka, J.M., Papakostas, G.I., Association of obesity and inflammatory marker levels on treatment outcome: results from a double-blind, randomized study of adjunctive L-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs. J. Clin. Psychiatry 76 (2015), 1635–1641.
76. Snitz, B.E., Weissfeld, L.A., Lopez, O.L., Kuller, L.H., Saxton, J., Singhabahu, D.M., Klunk, W.E., Mathis, C.A., Price, J.C., Ives, D.G., Cohen, A.D., McDade, E., Dekosky, S.T., Cognitive trajectories associated with beta-amyloid deposition in the oldest-old without dementia. Neurology 80 (2013), 1378–1384.
77. Snyder, H.R., Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. Psychol. Bull. 139 (2013), 81–132.
78. Svendsen, A.M., Kessing, L.V., Munkholm, K., Vinberg, M., Miskowiak, K.W., Is there an association between subjective and objective measures of cognitive function in patients with affective disorders?. Nord. J. Psychiatry 66 (2012), 248–253.
79. Talbot, K., Wang, H.Y., The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease. Alzheimers Dement 10 (2014), S12–S25.
80. Teramoto, S., Miyamoto, N., Yatomi, K., Tanaka, Y., Oishi, H., Arai, H., Hattori, N., Urabe, T., Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J. Cereb. Blood Flow. Metab. 31 (2011), 1696–1705.
81. van Bloemendaal, L., RG, I.J., Ten Kulve, J.S., Barkhof, F., Konrad, R.J., Drent, M.L., Veltman, D.J., Diamant, M., GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes 63 (2014), 4186–4196.
82. Vancampfort, D., Vansteelandt, K., Correll, C.U., Mitchell, A.J., De Herdt, A., Sienaert, P., Probst, M., De Hert, M., Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am. J. Psychiatry 170 (2013), 265–274.
83. Vos, T., Flaxman, A.D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J.A., Abdalla, S., Aboyans, V., Abraham, J., Ackerman, I., Aggarwal, R., Ahn, S.Y., Ali, M.K., Alvarado, M., Anderson, H.R., Anderson, L.M., Andrews, K.G., Atkinson, C., Baddour, L.M., Bahalim, A.N., Barker-Collo, S., Barrero, L.H., Bartels, D.H., Basanez, M.G., Baxter, A., Bell, M.L., Benjamin, E.J., Bennett, D., Bernabe, E., Bhalla, K., Bhandari, B., Bikbov, B., Bin Abdulhak, A., Birbeck, G., Black, J.A., Blencowe, H., Blore, J.D., Blyth, F., Bolliger, I., Bonaventure, A., Boufous, S., Bourne, R., Boussinesq, M., Braithwaite, T., Brayne, C., Bridgett, L., Brooker, S., Brooks, P., Brugha, T.S., Bryan-Hancock, C., Bucello, C., Buchbinder, R., Buckle, G., Budke, C.M., Burch, M., Burney, P., Burstein, R., Calabria, B., Campbell, B., Canter, C.E., Carabin, H., Carapetis, J., Carmona, L., Cella, C., Charlson, F., Chen, H., Cheng, A.T., Chou, D., Chugh, S.S., Coffeng, L.E., Colan, S.D., Colquhoun, S., Colson, K.E., Condon, J., Connor, M.D., Cooper, L.T., Corriere, M., Cortinovis, M., de Vaccaro, K.C., Couser, W., Cowie, B.C., Criqui, M.H., Cross, M., Dabhadkar, K.C., Dahiya, M., Dahodwala, N., Damsere-Derry, J., Danaei, G., Davis, A., De Leo, D., Degenhardt, L., Dellavalle, R., Delossantos, A., Denenberg, J., Derrett, S., Des Jarlais, D.C., Dharmaratne, S.D., Dherani, M., Diaz-Torne, C., Dolk, H., Dorsey, E.R., Driscoll, T., Duber, H., Ebel, B., Edmond, K., Elbaz, A., Ali, S.E., Erskine, H., Erwin, P.J., Espindola, P., Ewoigbokhan, S.E., Farzadfar, F., Feigin, V., Felson, D.T., Ferrari, A., Ferri, C.P., Fevre, E.M., Finucane, M.M., Flaxman, S., Flood, L., Foreman, K., Forouzanfar, M.H., Fowkes, F.G., Franklin, R., Fransen, M., Freeman, M.K., Gabbe, B.J., Gabriel, S.E., Gakidou, E., Ganatra, H.A., Garcia, B., Gaspari, F., Gillum, R.F., Gmel, G., Gosselin, R., Grainger, R., Groeger, J., Guillemin, F., Gunnell, D., Gupta, R., Haagsma, J., Hagan, H., Halasa, Y.A., Hall, W., Haring, D., Haro, J.M., Harrison, J.E., Havmoeller, R., Hay, R.J., Higashi, H., Hill, C., Hoen, B., Hoffman, H., Hotez, P.J., Hoy, D., Huang, J.J., Ibeanusi, S.E., Jacobsen, K.H., James, S.L., Jarvis, D., Jasrasaria, R., Jayaraman, S., Johns, N., Jonas, J.B., Karthikeyan, G., Kassebaum, N., Kawakami, N., Keren, A., Khoo, J.P., King, C.H., Knowlton, L.M., Kobusingye, O., Koranteng, A., Krishnamurthi, R., Lalloo, R., Laslett, L.L., Lathlean, T., Leasher, J.L., Lee, Y.Y., Leigh, J., Lim, S.S., Limb, E., Lin, J.K., Lipnick, M., Lipshultz, S.E., Liu, W., Loane, M., Ohno, S.L., Lyons, R., Ma, J., Mabweijano, J., MacIntyre, M.F., Malekzadeh, R., Mallinger, L., Manivannan, S., Marcenes, W., March, L., Margolis, D.J., Marks, G.B., Marks, R., Matsumori, A., Matzopoulos, R., Mayosi, B.M., McAnulty, J.H., McDermott, M.M., McGill, N., McGrath, J., Medina-Mora, M.E., Meltzer, M., Mensah, G.A., Merriman, T.R., Meyer, A.C., Miglioli, V., Miller, M., Miller, T.R., Mitchell, P.B., Mocumbi, A.O., Moffitt, T.E., Mokdad, A.A., Monasta, L., Montico, M., Moradi-Lakeh, M., Moran, A., Morawska, L., Mori, R., Murdoch, M.E., Mwaniki, M.K., Naidoo, K., Nair, M.N., Naldi, L., Narayan, K.M., Nelson, P.K., Nelson, R.G., Nevitt, M.C., Newton, C.R., Nolte, S., Norman, P., Norman, R., O'Donnell, M., O'Hanlon, S., Olives, C., Omer, S.B., Ortblad, K., Osborne, R., Ozgediz, D., Page, A., Pahari, B., Pandian, J.D., Rivero, A.P., Patten, S.B., Pearce, N., Padilla, R.P., Perez-Ruiz, F., Perico, N., Pesudovs, K., Phillips, D., Phillips, M.R., Pierce, K., Pion, S., Polanczyk, G.V., Polinder, S., Pope, C.A. 3rd, Popova, S., Porrini, E., Pourmalek, F., Prince, M., Pullan, R.L., Ramaiah, K.D., Ranganathan, D., Razavi, H., Regan, M., Rehm, J.T., Rein, D.B., Remuzzi, G., Richardson, K., Rivara, F.P., Roberts, T., Robinson, C., De Leon, F.R., Ronfani, L., Room, R., Rosenfeld, L.C., Rushton, L., Sacco, R.L., Saha, S., Sampson, U., Sanchez-Riera, L., Sanman, E., Schwebel, D.C., Scott, J.G., Segui-Gomez, M., Shahraz, S., Shepard, D.S., Shin, H., Shivakoti, R., Singh, D., Singh, G.M., Singh, J.A., Singleton, J., Sleet, D.A., Sliwa, K., Smith, E., Smith, J.L., Stapelberg, N.J., Steer, A., Steiner, T., Stolk, W.A., Stovner, L.J., Sudfeld, C., Syed, S., Tamburlini, G., Tavakkoli, M., Taylor, H.R., Taylor, J.A., Taylor, W.J., Thomas, B., Thomson, W.M., Thurston, G.D., Tleyjeh, I.M., Tonelli, M., Towbin, J.A., Truelsen, T., Tsilimbaris, M.K., Ubeda, C., Undurraga, E.A., van der Werf, M.J., van Os, J., Vavilala, M.S., Venketasubramanian, N., Wang, M., Wang, W., Watt, K., Weatherall, D.J., Weinstock, M.A., Weintraub, R., Weisskopf, M.G., Weissman, M.M., White, R.A., Whiteford, H., Wiersma, S.T., Wilkinson, J.D., Williams, H.C., Williams, S.R., Witt, E., Wolfe, F., Woolf, A.D., Wulf, S., Yeh, P.H., Zaidi, A.K., Zheng, Z.J., Zonies, D., Lopez, A.D., Murray, C.J., AlMazroa, M.A., Memish, Z.A., Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2163–2196.
84. Wallace, T.M., Levy, J.C., Matthews, D.R., Use and abuse of HOMA modeling. Diabetes Care 27 (2004), 1487–1495.
85. Wang, X.H., Li, L., Holscher, C., Pan, Y.F., Chen, X.R., Qi, J.S., Val8-glucagon-like peptide-1 protects against Abeta1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats. Neuroscience 170 (2010), 1239–1248.
86. Wolinsky, F.D., Vander Weg, M.W., Howren, M.B., Jones, M.P., Dotson, M.M., A randomized controlled trial of cognitive training using a visual speed of processing intervention in middle aged and older adults. PLoS One, 8, 2013, e61624.
87. Yamamoto, H., Lee, C.E., Marcus, J.N., Williams, T.D., Overton, J.M., Lopez, M.E., Hollenberg, A.N., Baggio, L., Saper, C.B., Drucker, D.J., Elmquist, J.K., Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J. Clin. Investig. 110 (2002), 43–52.
88. Yogi-Morren, D., Galioto, R., Strandjord, S.E., Kennedy, L., Manroa, P., Kirwan, J.P., Kashyap, S., Gunstad, J., Duration of type 2 diabetes and very low density lipoprotein levels are associated with cognitive dysfunction in metabolic syndrome. Cardiovasc. Psychiatry Neurol., 2014, 2014, 656341.